Document:

License Agreement made as of 11/1/2002

 EXHIBIT 10.34 
  
 License Agreement 
  
 AGREEMENT made as of the first day of November by and between THE ROCKEFELLER UNIVERSITY (“ROCKEFELLER”), an education corporation organized and
existing under the laws of the State of New York, having an office at 1230 York Avenue, New York, New York 10021-6399, and NEUROLOGIX, INC. (the “COMPANY,”) a corporation organized and existing under the laws of the State of Delaware
having an office at One Birch Plaza, Fort Lee, NJ 07024. 
  
 W I
T N E S S E T H: 
  
 WHEREAS, ROCKEFELLER is the owner of
certain valuable technology and know-how, as more fully described on Exhibit “A,” developed in the laboratory of Dr. Michael Kaplitt; 
  
 WHEREAS, COMPANY and ROCKEFELLER entered into exclusive License Agreements dated November 8, 1999 and April 16, 2001 (“Existing Licenses”)
relating to the valuable technology and know-how identified in Exhibit “A,” with the exception of the technology identified in such exhibit as “RU-533”; 
  
 WHEREAS, COMPANY and ROCKEFELLER desire to modify the terms of the Existing Licenses in the manner hereinafter provided, and
COMPANY desires to obtain the exclusive right and license in and to RU-533 to use, develop, manufacture, market and exploit the technology, together with relevant know-how for commercial development and application all in the manner hereinafter
provided. 
  
 NOW, THEREFORE, in consideration of the promises and
of the covenants and conditions contained herein, and intending to be bound hereby, the parties agree as follows: 
  
 1. DEFINITIONS 
  
 The following terms shall have the meaning assigned to them below when used in this Agreement: 
  
 1.1 “Party” shall mean either COMPANY or ROCKEFELLER;
“Parties” shall mean both COMPANY and ROCKEFELLER. 
  
 1.2 “Licensed Patent Rights” shall mean: 
  
 (a) the patent applications and patents set forth in Exhibit “A”; and 
  
 (b) all patent applications which are divisions, continuations, continuations-in-part, reissues, renewals, foreign counterparts,
extensions or additions of the application described in Exhibit A hereof, and all patents which may issue thereon. 
  
 1.3 “Technical Information” shall mean any and all technical data, information, materials and know-how owned by ROCKEFELLER, existing in a
tangible form and available for transfer to COMPANY, at the date of this Agreement or which may during the term of the license hereunder be developed and be available for licensing by ROCKEFELLER, and which is needed in the practice of Licensed
Patent Rights. 

 1.4 “Territory” shall mean the World. 
  
 1.5 “Product(s)” shall mean any and all products which embody or
the manufacture or use of which employ Licensed Patent Rights or Technical Information. 
  
 1.6 “Exchange Product(s)” shall mean any and all products COMPANY acquires as a result of exchanging technology described and claimed in Licensed Patent Rights with an unrelated third party. 
  
 1.7 “Net Sales” shall mean the total price received by COMPANY and
its sublicensees for Products sold in each country in which COMPANY has received governmental approval in the subject country to commercially market and sell said Product in such country, less normal deductions which reduce the amount actually
received by the seller, such as sales taxes, agency commissions, refunds, rebates, allowances for return of goods for defective quality, and freight or cash discounts. 
  
 1.8 “Effective Date” shall mean the day and year as first written above. 
  
 1.9 “Invention” shall, as used in section 4.2, comprise the patent
applications and patents relating to a single Rockefeller case number (“RU xxx”) under the patent rights specified in Exhibit A. For example, a Licensed Product that practices or employs multiple patents that arose from a single RU case
number practices or employs one “Invention,” whereas a Licensed Product that practices or employs two patents, each of which arose from a different RU case number, practices or employs two “Inventions.” 
  
 2. LICENSE GRANT; WARRANTY; OWNERSHIP OF MODIFICATIONS 
  
 2.1 This Agreement is intended by the parties to restate, amend, and
supercede the Existing Licenses, which shall, upon the effective date of this Agreement, no longer control the parties’ relationship with respect to the subject matters addressed therein. 
  
 2.2 ROCKEFELLER hereby grants to COMPANY the sole and exclusive right and
license with the right to sublicense under Licensed Patent Rights and Technical Information to make, have made, use and sell Products in the Territory, except to the extent that ROCKEFELLER’s right to do so may be limited under the provisions
of 35 United States Code, et seq., Section 201, and regulations and rules promulgated thereunder. 
  
 2.3 The COMPANY’s right to sublicense granted by ROCKEFELLER under the License is subject to each of the following conditions: 
  
 (a) In each sublicense agreement, COMPANY will prohibit the
sublicensee from further sublicensing and require that the sublicensee comply with the terms and conditions of this Agreement. 
  
 (b) Within thirty (30) days after COMPANY enters into a sublicense agreement, COMPANY will deliver to ROCKEFELLER a complete and accurate
copy of the entire sublicense agreement written in the English language. ROCKEFELLER’s receipt of the sublicense agreement, however, will constitute neither an approval of the sublicense nor a waiver of any right of ROCKEFELLER or obligation of
COMPANY under this Agreement. 
  
 (c)
COMPANY’s execution of a sublicense agreement will not relieve COMPANY of any of its obligations under this Agreement. COMPANY is primarily liable to ROCKEFELLER for 
  

 2 

 any act or omission of an Affiliate or sublicensee that would be a breach of this Agreement if performed
or omitted by COMPANY, and COMPANY will be deemed to be in breach of this Agreement as a result of such act or omission. 
  
 2.4 ROCKEFELLER represents and warrants that it has all necessary title, right and power to grant the licenses and rights granted hereunder, free and
clear of any liens, claims or encumbrances. 
  
 2.5 All
modifications to the Licensed Patent Rights and Technical Information developed solely by COMPANY shall be the exclusive property of COMPANY. 
  
 3. PATENTS 
  
 3.1 ROCKEFELLER shall select qualified independent patent counsel reasonably acceptable to COMPANY to prepare, file, prosecute and maintain all patent
applications included in the Licensed Patent Rights. Such counsel shall interact with COMPANY under the terms of a Client and Billing Agreement in the form attached as Exhibit B. COMPANY shall be entitled to determine the countries in which it
wishes to obtain and maintain patent protection under this Agreement, and patent applications shall be filed in such countries by ROCKEFELLER. 
  
 3.2 COMPANY shall be free, at any time and at its sole option, to abandon patent prosecution or maintenance with respect to any patent application or
patent within the Licensed Patent Rights in any country of the Territory. COMPANY shall promptly advise ROCKEFELLER of its election not to proceed with and/or to abandon the preparation, filing, prosecution, or maintenance of any patent application
or patent licensed hereunder at least thirty (30) days before a due date to allow ROCKEFELLER at its own cost to effectuate such preparation, filing, prosecution, or maintenance if it so desires; and COMPANY shall, at the request of ROCKEFELLER,
take whatever reasonable steps may be necessary or appropriate to return to ROCKEFELLER all rights licensed from ROCKEFELLER with respect to the applicable Licensed Patent Rights which it proposes to abandon. Nothing herein is intended or shall be
construed as obligating ROCKEFELLER to apply for any U.S. or foreign patents at its own expense, or to defend any patent or patent application that may be included in Licensed Patent Rights hereunder. Nothing herein is intended or shall be construed
as obligating COMPANY to maintain its license with respect to any patent or application which may be included in the Licensed Patent Rights hereunder or to continue to finance the preparation, filing, prosecution or maintenance of any patent
application or patent in any country or jurisdiction. 
  
 3.3
Except in accordance with the exercise of its rights to abandon patent prosecution or maintenance pursuant to Section 3.2 hereof, COMPANY shall continue to reimburse ROCKEFELLER for filing, prosecution, and maintenance costs associated with the
Licensed Patent Rights actually incurred by ROCKEFELLER with respect to each such patent application or patent licensed hereunder during the term this Agreement. 
  
 4. FEES AND ROYALTIES 
  
 4.l Upon execution of the Agreement, COMPANY will issue to ROCKEFELLER, as partial consideration for the License, shares of Common Stock of COMPANY as
will cause ROCKEFELLER to own two and one-half percent (2.5%) of the capital stock of COMPANY on a fully diluted basis. The issuance of equity will be pursuant to a Stock Purchase Agreement substantially in the form attached hereto as Exhibit C.

  

 3 

 4.2 In further consideration of the rights and licenses granted hereunder, COMPANY shall pay or cause to
be paid to ROCKEFELLER amounts, as follows: 
  
 (a) benchmark
payments as follows for each Product: 
  
 (i)
upon filing for BLA/PLA: $50,000 
  
 (ii) upon
FDA approval of the BLA/PLA: $200,000 
  
 (b) royalties on Net
Sales of a Product and Exchange Product that practices or employs only one Invention under the Licensed Patent Rights, as follows: 
  
 (i) xxx percent (xxx%) of the Net Sales under Five Hundred Million ($500,000,000) Dollars; 
  
 (ii) xxx percent of the Net Sales over Five Hundred Million
($500,000,000) Dollars. 
  
 (c) royalties of xxx (xxx%) percent of
the Net Sales of a Product and Exchange Product that practices or employs more than one Invention under the Licensed Patent Rights. 
  
 (d) sublicense income as follows: xx (xx%) percent of the consideration, including upfront license fees and milestone payments, but excluding any
royalties based on Net Sales, actually received by COMPANY from a third party for a sublicense to the Licensed Patent Rights and Technical Information. 
  
 The obligation to pay royalties hereunder is imposed only once with respect to the sale of a Product regardless of the number of patents or valid claims
which cover such Product. There shall be no obligation to pay ROCKEFELLER royalties pursuant to Section 4.2 (b) hereof on sale of Products by COMPANY to its sublicensees for resale, but in such instances, the obligation to pay royalties shall arise
upon the sale by COMPANY or its sublicensees to unrelated third parties. 
  
 4.3 ROCKEFELLER agrees to use reasonable efforts, short of litigation, to resist any claim which might effect the exclusive nature of any license granted hereunder. Should it develop at any time during the term of
this Agreement, however, that the license granted herein is rendered non-exclusive in any country of the Territory as a result of any governmental, judicial or other action, then the royalty provided in Paragraph 4.2(b) hereof due to ROCKEFELLER
from COMPANY on the affected product in that country shall be reduced by one half. 
  
 4.4 Upon commencement of commercial sales of any Products which generate a royalty to ROCKEFELLER pursuant to this Agreement, COMPANY shall, within ninety (90) days from June 30th and December 31st of each year, make
semi-annual reports to ROCKEFELLER showing the total Net Sales of Products sold, leased or otherwise disposed of during such period and the calculation of royalties thereon. Any royalty then due and payable shall be included with such report. All
amounts that are not paid when due will accrue interest from the date due until paid at a rate equal to one and one-half percent (1.5%) per month (or the maximum allowed by law, if less). COMPANY’s records shall be open to inspection by
ROCKEFELLER or a certified public accountant designated by ROCKEFELLER, at reasonable times and upon reasonable notice no more frequently than once per year, for the sole purpose of verifying the accuracy of the reports and royalty payments.

  
 4.5 ROCKEFELLER hereby represents that it has no knowledge of
any charges that the Licensed Patent Rights infringe any rights of any third parties. ROCKEFELLER further represents that it has no knowledge of any infringement of any of the Licensed Patent Rights. COMPANY shall have the right but not the
obligation, in its own name, to institute patent infringement proceedings against third 
  

 4 

 parties based on any Licensed Patent Rights licensed hereunder. In the event that COMPANY institutes patent infringement
proceedings, COMPANY shall have the right to litigate and/or settle such patent infringement proceedings for such amounts as it determines to be reasonable in COMPANY’s sole discretion. If COMPANY does not institute infringement proceedings
against such third parties, ROCKEFELLER shall have the right but not the obligation, to institute such proceedings. The expenses of such proceedings, including lawyers’ fees, shall be borne by the Party instituting suit. Each Party shall
execute all necessary and proper documents and take all other appropriate action to allow the other Party to institute and prosecute such proceedings. Any award paid by third parties as a result of such proceedings (whether by way of settlement or
otherwise) shall first be applied toward reimbursement for the legal fees and expenses incurred, and the excess, if any, shall be shared on a pro rata basis based on the expenses incurred by each party. So long as such infringement proceedings
continue, COMPANY shall be permitted to reserve any royalty due to ROCKEFELLER on sales of the affected Product in the country in question until such time as the proceedings have been concluded. If the patent is finally held to be valid and
infringed by any such third party, the reserved royalty shall thereupon be promptly paid to ROCKEFELLER; if such patent is finally held to be unenforceable or invalid, then ROCKEFELLER shall not be entitled to the reserved royalty and no further
royalty shall be due by COMPANY or its sublicensee under that patent; royalties theretofore paid may be retained, however. 
  
 4.6 Should COMPANY in any calendar year be required to pay royalties in any country under third party patents in order to make, use, or sell a Product
hereunder, COMPANY shall have the right to deduct such royalties from any royalties due ROCKEFELLER in that country, up to a maximum of fifty (50) cents for each dollar of royalty owed to ROCKEFELLER in that country, provided, however,
that the royalty owed to ROCKEFELLER shall never be less than one-half (l/2) of the amount due under the applicable royalty rate. In the event such unlicensed competition should render it impossible for COMPANY to make an acceptable profit in any
country of the Territory, the Parties shall meet to discuss an appropriate further reduction in the royalty due ROCKEFELLER for that country. 
  
 4.7 Should COMPANY decide at any time during the term hereof that it will no longer commercially pursue development of any invention licensed hereunder,
COMPANY shall promptly notify ROCKEFELLER of its decision and upon request from ROCKEFELLER, shall take whatever steps are necessary to assure reversion to ROCKEFELLER of all rights to the Licensed Patent Rights. 
  
 4.8 ROCKEFELLER shall have the right to terminate this license at any time
after, with respect to U.S. Patent No. 6,040,172, three (3) years from the date of license, or, with respect to the other Licensed Patent Rights, five (5) years from the date of license, if, in ROCKEFELLER’s reasonable judgment taking into
account the normal course of such programs conducted with sound and reasonable business practices and judgment, and any reports provided, COMPANY: 
  
 (a) has not filed a New Drug Application, or its equivalent, for a Product with the United States Food and Drug Administration, directly
or through a sublicensee and is not keeping such Product reasonably available to the Public, and 
  
 (b) is not demonstrably engaged in research, development, manufacturing, marketing or sublicensing program, as appropriate, directed
toward this end. 
  
 4.9 The licenses herein granted shall
continue for the lives of any patents hereunder as the same or the effectiveness thereof may be extended by any governmental authority, rule or regulation applicable thereto. Thereafter, upon expiration of all Licensed Patent Rights in a country,
COMPANY shall have a fully paid up license to make, have made, use and sell the Product(s) for any use in that country. 
  

 5 

 5. PUBLICITY 
  
 Except as may be required by law or may be a required disclosure in COMPANY’s filings with the United States Securities and Exchange Commission,
COMPANY will not use directly or by implication the name of ROCKEFELLER, or the name of any member of the faculty or staff of ROCKEFELLER, or any unpublished information or data relating to the investigation without the prior written approval of
ROCKEFELLER and the faculty or staff member involved, which consent shall not be unreasonably withheld. 
  
 6. INDEMNIFICATION; INSURANCE 
  
 6.1 COMPANY will defend, indemnify and hold harmless ROCKEFELLER and its trustees, officers, agents and employees (each, an “Indemnified Party”) from and against any and all liability, loss, damage, action, claim, or expense
suffered or incurred by the Indemnified Parties, including attorneys’ fees and expenses (collectively, “Liabilities”), arising out of or resulting from: 
  
 (a) the development, testing, use, manufacture, promotion, sale or other disposition of any Licensed Patent
Rights or Products by COMPANY, its affiliates, sublicensees, assignees or vendors or third parties; 
  
 (b) any material breach of this Agreement by COMPANY or its affiliates or sublicensees; and 
  
 (c) the enforcement of this Article 6 by any Indemnified
Party. 
  
 Liabilities include, but are not limited to:

  
 (x) any product liability or other claim of
any kind related to use by a third party of a Product that was manufactured, sold or otherwise disposed of by COMPANY, its affiliates, sublicensees, assignees or vendors or third parties; 
  
 (y) a claim by a third party that the Licensed Patent Rights
or the design, composition, manufacture, use, sale or other disposition of any Product infringes or violates any patent, copyright, trade secret, trademark or other intellectual property right of such third party; and 
  
 (z) clinical trials or studies conducted by or on behalf of
COMPANY, its affiliates, sublicensees, assignees or vendors or third parties relating to the Licensed Patent Rights or the Products, such as claims by or on behalf of a human subject of any such trial or study. 
  
 6.2 COMPANY will not settle or compromise any claim or action giving rise to
Liabilities in any manner that imposes any restrictions or obligations on ROCKEFELLER or grants any rights to the Licensed Patent Rights or Products without ROCKEFELLER’s prior written consent, which shall not unreasonably be withheld. If
COMPANY fails or declines to assume the defense of any claim or action within thirty (30) days after notice of the claim or action, then ROCKEFELLER may assume the defense of such claim or action for the account and at the risk of COMPANY, and any
Liabilities related to such claim or action will be conclusively deemed a liability of COMPANY. The indemnification rights of the Indemnified Parties under this Article 6 are in addition to all other rights that an Indemnified Party may have at law,
in equity or otherwise. 
  
 6.3 COMPANY will procure and maintain
insurance policies for the following coverages with respect to personal injury, bodily injury and property damage arising out of COMPANY’s performance under this Agreement: 
  
 (a) during the Term, comprehensive general liability, including broad form and contractual liability, in a
minimum amount of $2,000,000 combined single limit per occurrence and in the aggregate; 
  

 6 

 (b) prior to the commencement of clinical trials involving Products, clinical trials
coverage in a minimum amount of $2,000,000 combined single limit per occurrence and $5,000,000 in the aggregate; and 
  
 (c) prior to the sale of the first Product, product liability coverage, in a minimum amount of $2,000,000 combined single limit per
occurrence and $5,000,000 in the aggregate. 
  
 ROCKEFELLER may
review periodically the adequacy of the minimum amounts of insurance for each coverage required by this Section 6.3, and ROCKEFELLER reserves the right to request that COMPANY adjust the limits accordingly, which COMPANY shall consider in good
faith. The required minimum amounts of insurance do not constitute a limitation on COMPANY’s liability or indemnification obligations to ROCKEFELLER under this Agreement. 
  
 6.4 The policies of insurance required by Section 6.3 will be issued by an insurance carrier with an A.M. Best rating of
“A” or better and will name ROCKEFELLER as an additional insured with respect to COMPANY’s performance under this Agreement. COMPANY will provide ROCKEFELLER with insurance certificates evidencing the required coverage within thirty
(30) days after the commencement of each policy period and any renewal periods. Each certificate will provide that the insurance carrier will notify ROCKEFELLER in writing at least thirty (30) days prior to the cancellation or material change in
coverage. 
  
 7. NOTICES 
  
 Any Notice required to be given pursuant to this Agreement shall be made by
personal delivery, by courier service or, if by mail, by registered or certified mail, return receipt requested, by one Party to the other Party at the addresses noted below. 
  
 In the case of COMPANY, notice shall be sent to: 
  
 Neurologix, Inc. 
 c/o Palisade Capital Management, L.L.C. 
 One Bridge Plaza 
 Fort Lee, New Jersey 07024 
 Attention: Mr.
Mark S. Hoffman 
 Fax Number: (718) 747-0569 
  
 With a copy to: 
  
 Neurologix, Inc. 
 271-32 E. Grand Central
Parkway 
 Floral Park, NY 11005 
 Attention: Dr. Martin J. Kaplitt, President 
 Fax Number: (718) 229-3804 
  

 7 

 In the case of ROCKEFELLER, notice shall be sent to: 
  
 The Rockefeller University 
 1230 York Avenue, Box 81 
 New York, New York
10021-6399 
 Attn: Office of Technology Transfer 
  
 8. LAW TO GOVERN 
  
 This Agreement shall be interpreted and governed in accordance with the laws of the State of New York, without regard to such State’s conflicts of
law or choice of law provisions. 
  
 9. ASSIGNMENT 
  
 This Agreement may not be assigned by either Party without the prior written
consent of the other. Notwithstanding the foregoing, COMPANY may assign this Agreement without the consent of ROCKEFELLER to a purchaser or successor-in-interest in the event of a merger, consolidation, or sale of substantially all of COMPANY’s
stock or assets or business and/or pursuant to any reorganization qualifying under section 368 of the Internal Revenue Code of 1986 as amended, as may be in effect at such time, provided that such successor-in-interest or purchaser agrees in writing
to assume all of LICENSEE’s obligations under this Agreement. 
  
 10.
TERMINATION 
  
 10.1 This Agreement shall remain in full
force and effect until terminated as provided herein. COMPANY shall have the right to terminate this Agreement at any time upon ninety (90) days’ prior written Notice to ROCKEFELLER. Such termination shall automatically terminate the license
provided in Section 2 hereof, but shall not relieve COMPANY of the obligation to pay royalties for any period prior to the effective date of termination. In the event of such termination, COMPANY agrees to deliver to ROCKEFELLER all test, clinical,
and other technical data developed by COMPANY concerning the Technical Information and/or Licensed Patent Rights, and ROCKEFELLER shall have the right to use such data thereafter in any manner it deems fit, including, but not limited to, the
licensing of third parties. 
  
 10.2 Either Party may terminate
this Agreement in the event of a material breach by the other Party, provided only that the offending Party is given notice of the breach and a reasonable time, not to exceed sixty (60) days, in which to cure such breach. 
  
 10.3 Any termination of this Agreement and/or license granted hereunder shall
also terminate any sublicense. 
  
 11. RESOLUTION OF DISPUTES 

 
 The Parties agree that in the event of a dispute between them arising
from, concerning, or in any way relating to this Agreement, the Parties shall undertake good faith efforts to resolve the same amicably between themselves. If such dispute is not resolved within a commercially reasonable period of time, either Party
may submit the dispute to arbitration under the rules of the American Arbitration Association. Such arbitration shall be held at the location of the Party that did not submit the dispute to Arbitration. 
  

 8 

 12. FORCE MAJEURE 
  
 The Parties shall not be liable in any manner for failure or delay in fulfillment of all or part of this Agreement, directly or indirectly caused by acts
of God, governmental orders or restrictions, war, war-like condition, revolution, riot, looting, strike, lockout, fire, flood or other similar or dissimilar causes or circumstances beyond the non-performing Party’s control. The non-performing
Party shall promptly notify the other Party of the cause or circumstance and shall recommence its performance of its obligations as soon as practicable after the cause or circumstance ceases. 
  
 13. ENTIRE UNDERSTANDING 
  
 This Agreement represents the entire understanding between the Parties
concerning the subject matter hereof. 
  
 IN WITNESS WHEREOF, the
Parties have caused this Agreement to be duly executed as of the day and year first above written. 
  

			
	 NEUROLOGIX, INC.

		
	By:	 	 /s/    Martin J. Kaplitt        

	 	 	

	 	 	Martin J. Kaplitt, M.D.
	 Title:
	 	President
	 Date:
	 	12/26/02

  

			
	THE ROCKEFELLER UNIVERSITY
		
	By:	 	 /s/    Thomas P. Sakmar        

	 	 	

	 	 	Thomas P. Sakmar, M.D.
	Title:	 	Acting President
	Date:	 	12/19/02

  

 9Clinical Study Agreement dated 4/2/2003

 EXHIBIT 10.35 
  
 Cornell University for its Medical College 
 Research and Sponsored Programs 
 1300 York Avenue 
 New York, N.Y. 10021 
  
 Clinical Study Agreement 
  
 This CLINICAL STUDY AGREEMENT (the “Agreement”) between Cornell University for its Medical College, hereinafter referred to as “the Medical
College,” and Neurologix, Inc., hereinafter referred to as the “Sponsor,” is entered into as of July 2, 2003 (“Effective Date”). 
  
 WHEREAS, the program contemplated by this Agreement, consisting of a clinical study in accordance with the Protocol titled “Clinical Research in Patients
affected by Parkinson’s Disease Using Direct Delivery of the GAD genes in the Brain” (“Protocol”) (a copy of the Protocol is attached hereto as Attachment A), is of mutual interest and benefit to the Medical College and to the
Sponsor, and will further the instructional and research objectives of the Medical College in a manner consistent with its status as a non-profit, tax-exempt, educational institution, 
  
 NOW, THEREFORE, the parties hereto agree as follows: 
  

	1.	THE SCOPE OF WORK. The Medical College agrees to use all reasonable efforts to perform the clinical study in accordance with the Protocol (the “Study”).

  

	2.	PRINCIPAL INVESTIGATOR. The Study will be supervised by Dr. Michael G. Kaplitt (the “Principal Investigator”). If, for any reason, s(he) is unable to continue to
serve as Principal Investigator, and a successor acceptable to both the Medical College and the Sponsor is not available, this Agreement shall be terminated as provided in Article 5. 

  

	3.	PERIOD OF PERFORMANCE. The Study shall be conducted on twelve patients in accordance with the Protocol. 

  

	4.	PAYMENT/REIMBURSEMENT OF COSTS. Payments shall be made to the Medical College by the Sponsor in advance in U.S. dollars, net of taxes or impost of any kind, on the terms and
schedule set forth in Attachment B. 

  

	5.	TERMINATION. Performance under this Agreement may be terminated by the Sponsor upon thirty (30) days prior written notice. Performance may be terminated by the Medical
College if circumstances beyond its reasonable control preclude continuation of the Study. Upon termination, the Medical College will be reimbursed as specified in Article 4 for all costs incurred in the performance of the Study prior to the
termination, and any non-cancelable commitments incurred in the performance of the Study, such reimbursement not to exceed the total estimated project costs specified in Article 4. 

  

	6.	PUBLICATIONS AND COPYRIGHTS. The Medical College will be free to publish the results of the Study after providing the Sponsor with a thirty (30) day period in which to review
each publication to identify patentable subject matter, and to identify any inadvertent disclosure of the Sponsor’s proprietary information. Medical College will not disclose Sponsor’s confidential information without permission. Sponsor
shall not have editorial rights over manuscripts or 

  
  

 presentations, but may comment on implications of publication timing for multiple site studies or request
deletion of Sponsor’s confidential or proprietary information. If necessary to permit the preparation and filing of U.S. patent applications, the Principal Investigator may agree to an additional review period not to exceed sixty (60) days. Any
further extension will require subsequent agreement between the Sponsor and the Medical College. 
  
 The Sponsor will be given full credit and acknowledgment for the support provided to the Medical College in any publication resulting from this research.
Medical College will retain ownership of its copies of all completed case report forms. Title to, and the right to determine the disposition of, any copyrights, or copyrightable material, first produced or composed in the performance of this
research, shall remain with the Medical College. The Medical College shall grant to the Sponsor an irrevocable, royalty-free, perpetual, non-exclusive right to reproduce, translate, and use all such research data (including any informational
database into which such data is entered) and copyrighted material (excluding computer software and its documentation and/or informational databases other than those containing research data) for its own purposes, including, but not limited to,
submission to the United States Food and Drug Administration. ,. 
  

	7.	A. INVENTIONS AND PATENTS. The Medical College will disclose each subject invention to the Sponsor within two months after the inventor discloses it in writing to the Medical
College personnel responsible for patent matters. The disclosure to the Sponsor shall be in the form of a written report and shall identify the funding Agreement under which the invention was made and the inventor(s). 

  
 If, with respect to a Medical College Invention (as defined below) the
Sponsor requests a license in a reported invention within 45 days of receipt of the invention report, the Medical College: 
  

	 	(a)	Will use reasonable efforts to solicit US Patent protection; 

  

	 	(b)	Will negotiate in good faith a license with reasonable initial payments, royalties, and minimum royalties; and 

  
 If foreign patent rights are available, they will be pursued and licensed at
the Medical College’s sole discretion, but shall be the subject of any exclusive license negotiation. 
  
 B. INTELLECTUAL PROPERTY. 
  

	 	(a)	Title to Inventions Based On Sponsor Information. To the extent that Sponsor is providing confidential information to the Medical College and Principal Investigator, and to the
extent that the Sponsor has authored the Protocol to be conducted under this Agreement, and has designed and structured the manner in which the work is to be conducted, all inventions and discoveries, whether or not patentable, made in the
performance of the Study and that incorporates Sponsor’s Study therapy, drug or device, including new uses (collectively, “Sponsor Inventions”), shall be solely and exclusively owned by Sponsor, and Medical College and Principal
Investigator hereby assign all of their right, title and interest in and to such Sponsor Inventions to Sponsor. In instances in which the Sponsor desires to secure protection on such inventions, the Principal Investigator will cooperate with the
Sponsor, at Sponsor’s expense, for the purpose of filing and prosecuting patent applications, the cooperation to include the execution of any and all lawful papers which may be deemed necessary or desirable by the Sponsor for the filing and
prosecution of applications and for assignment of the same to the Sponsor, including all declarations, oaths, specifications, and instruments of assignment for filing and recordation in the U.S. and foreign Patent Offices. 

 
  

	 	(b)	Title to Other Inventions. For inventions other than Sponsor Inventions, title to any invention conceived or first reduced to practice in the performance of the Study (“Medical
College Inventions”) shall remain with the Medical College. Sponsor shall be notified of any such invention promptly after a disclosure is received by the Medical College Technology Licensing Office. The Medical College (1) may file a patent
application at the request of the Sponsor and at the Sponsor’s expense; or (2) may file a patent application at its own discretion. 

  

	 	(c)	Licensing Options. WMC grants to the Sponsor an option to negotiate an exclusive, royalty-bearing license under the Medical College Inventions on reasonable terms and conditions to
be agreed upon by the parties within sixty (60) days of receipt of the invention report. 

  

	 	(d)	Confidentiality of Invention Disclosures. The Sponsor shall retain all invention disclosures submitted to Sponsor by the Medical College in confidence and use all reasonable efforts
to prevent their disclosure to third parties. The Sponsor shall be relieved of this obligation only when this information becomes publicly available through no fault of the Sponsor. 

  

	8.	PROPRIETARY DATA. The Medical College’s acceptance and use of any proprietary data which may be supplied by the Sponsor in the course of this research project shall be
subject to the following: 

  

	 	(a)	The data must be marked or designated in writing as proprietary to the Sponsor. 

  

	 	(b)	The Medical College retains the right to refuse to accept any such data which it does not consider to be essential to the completion of the project or which it believes to be
improperly designated, or for any reason. 

  

	 	(c)	Where the Medical College does accept such data as proprietary, it agrees to exercise its best efforts not to publish or otherwise reveal the data to others outside the Medical
College without the permission of the Sponsor, unless the data has already been published or disclosed publicly by third parties or is required to be disclosed by order of a court of law. 

  

	 	(d)	The Medical College shall hold proprietary information in confidence for a period not to exceed 3 years from the termination date of this Agreement. 

  

	9.	USE OF NAMES. Neither party will use the name of the other in any advertising or other form of publicity without the written permission of the other; in the case of the
Medical College, that of the Dean and University Counsel. 

  

	10.	REPORTS. A final report of the progress of the work shall be made to the Sponsor by the Principal Investigator within three months of completion. For projects lasting more
than six months, interim reports may be requested by the Sponsor at no more than four-month intervals. 

  

	11.	CHANGES. The Sponsor or the Medical College may, at any time, in writing to each other, suggest and by mutual written agreement make changes within the general scope of the
work, including but not limited to: 

  

	 	(a)	revising or adding to the work or deleting portions thereof, 

  

	 	(b)	revising the period or schedule of performance, or 

  

	 	(c)	increasing or decreasing the total cost. 

  
 Upon receipt of such notice of change and their mutual written agreement thereto, the parties shall immediately use their best efforts to take all
necessary steps to comply therewith. 
  

	12.	INDEMNIFICATION. The Sponsor agrees to indemnify the Medical College, its officers, trustees, overseers, agents, and employees, and any affiliated hospitals, clinics or other
institutions affiliated with the Medical College at which the Study may be conducted, and hold them harmless from any demands, claims, lawsuits, costs of defense or costs of judgments that may be made or instituted against any of them by reason of
injury (including death) to any person, or damage to property, arising out of or connected with performance of the Study by the Medical College, provided, however, Sponsor will have no liability for loss or damage resulting from, and no duty to
indemnify with respect to: (i) failure of the Medical College to adhere to the terms of the Protocol or Sponsor’s written instructions concerning use of the Study therapy, drug or device, (ii) failure by the Medical College to comply with
applicable FDA or other government requirements, or (iii) negligence (including medical malpractice) or willful malfeasance by the Medical College, its trustees, officers, agents and employees, but only to the extent that such demands, claims or
judgments are due to the negligence or willful malfeasance of the Medical College, its trustees, officers, agents and employees. 

  

	13.	INSURANCE. The Sponsor shall provide evidence that the Sponsor has sufficient liability insurance and other adequate forms of protection, reasonably deemed acceptable by the
Medical College, to satisfy the indemnification obligations set forth in section 12 of this Agreement on or before one week prior to the first patient receiving treatment in accordance with the Protocol,. Such evidence shall be in the form of a
certificate of insurance or, in the case of self-insurance, a letter accompanying the Sponsor’s audited financial statements in which an authorized official of the Sponsor indicates that the Sponsor has sufficient assets to cover potential
losses which might arise in connection with the Sponsor’s indemnification obligations. The Medical College will inform the Sponsor whether its evidence of insurance (or other form of protection) and the adequacy thereof are acceptable.

  

	14.	NOTICES. All communications, reports, and notices required or permitted hereunder shall be deemed sufficiently given if in writing and personally delivered or sent by
registered mail, postage prepaid, return receipt requested, addressed to the parties as follows or at such other address as a party shall have given notice of pursuant hereto: 

  
 If to the Medical College: 
  
 Senior Director for Grants & Contracts 
 Office of Research & Sponsored Programs 
 Weill Medical College of Cornell University 
 1300 York Avenue, Room A-131 
 New York, New York 10021 
 Telephone: (212) 746-6020 
 Facsimile: (212) 746-6938 
  
 If to the sponsor: 
  
 Neurologix, Inc. 
 c/o Palisade Capital Management, L.L.C. 
 One Bridge Plaza 
 Fort Lee, New Jersey 07024 
  

 Attention: Mr. Mark S. Hoffman 
 Fax Number: 201-585-9798 
  
 With a copy to: 
  
 Neurologix, Inc. 
 271-32 E. Grand Central Parkway 
 Floral Park, NY 11005 
 Attention: President 
 Fax Number: (718) 747-0569 
  

	15.	LAWS AND REGULATIONS. This Agreement shall be governed by, and construed and enforced in accordance with, the Laws of the State of New York. The Sponsor shall cooperate with
the Medical College in complying with any applicable Federal, state and local laws, regulations and policies governing research. Medical College represents that neither Medical College nor any person Medical College employs in performance of the
Study is debarred under section 306 of the Federal Food, Drug and Cosmetics Act. 

  

	16.	EXPORT CONTROLS. It is understood that the Medical College is subject to United States laws and regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities, and that its obligations hereunder are contingent on compliance with applicable U.S. export laws and regulations (including the Arms Export Control Act, as amended, and the Export Administration Act of
1979). The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by the Sponsor that the Sponsor will not re-export data or commodities to certain
foreign countries without prior approval of the cognizant government agency. While the Medical College agrees to cooperate in securing any license which the cognizant agency deems necessary in connection with this Agreement, the Medical College
cannot guarantee that such licenses will be granted. 

  

	17.	ASSIGNMENT. This Agreement may not be assigned by either party without the prior written consent of the other party. Notwithstanding the foregoing, the Sponsor may assign
this Agreement without the consent of the Medical College to a purchaser or successor-in-interest in the event of a merger, consolidation, or sale of substantially all of Sponsor’s stock or assets or business and/or pursuant to any
reorganization qualifying under section 368 of the Internal Revenue Code of 1986 as amended, as may be in effect at such time, provided that such successor-in-interest or purchaser agrees to assume all of Sponsor’s obligations under this
Agreement. 

  

	18.	ORDER OF PRECEDENCE. The parties hereby agree, that in the event of a conflict between the terms and conditions of the Contract Document itself, and any other Document either
incorporated by reference or attached to the Contract, the terms and conditions of the basic Contract Document itself shall prevail. 

  

	19.	ENTIRE AGREEMENT. This Agreement, including all Exhibits referenced herein, shall be the complete Agreement of the parties hereto and shall supersede all prior agreements and
understandings, oral or written, between the parties respecting the subject matter hereof. 

  
 The respective parties have executed this Agreement on the dates indicated below. 
  

					
	 CORNELL UNIVERSITY
 FOR ITS MEDICAL
COLLEGE
	 	 	 	NEUROLOGIX, INC.
			
	 /s/    Steven P. Rosalie        

	 	 	 	 /s/    Mark S. Hoffman        

	Medical College Official	 	 	 	 Mark S. Hoffman
 Secretary
Treasurer

			
	 Steven P. Rosalie        

	 	 	 	 
	Typed Name	 	 	 	 
			
	 Associate Treasurer

	 	 	 	 7/2/03

	 Title
	 	 	 	 Date

			
	 7/8/03

	 	 	 	 
	 Date
	 	 	 	 

  
 I agree to act as Principal
Investigator for the project described above: 
  

	
	
	 /s/    Michael G. Kaplitt        

	

	Dr. Michael G. Kaplitt

  

	
	
	 7/8/03

	 Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]